Pre-Clinical Pipeline
Both pre-clinical assets pipelines are available for partnering opportunities.
Kv3.1/3.2 Program
Bionomics’ molecules target Kv3.1/3.2 ion channels on Parvalbumin (+), GABAergic interneurons in the pre-frontal cortex. These small molecule Kv3.1 / Kv3.2 potassium ion channels activators have potential for improving cognitive dysfunction and negative symptoms in schizophrenia and other illnesses such as Autism Spectrum Disorder and Alzheimer’s Disease.
Pan Nav Program
Bionomic’ Pan Nav inhibitors were selected out of more than 1000 synthesized compounds, with 2 patents filed for the lead and backup compounds. These small molecules have functional selectivity for voltage gated sodium channels: Nav1.7, Nav1.8 and potentially Nav1.9.
Gain & Loss-of-function mutations in Nav1.7, 1.8 and 1.9 are associated with human pain syndromes where extreme pain or no pain is experienced. Therefore Pan Nav (1.7/1.8/1.9) inhibitors may be a potential treatment for chronic pain and other potentially large unmet medical needs.
The lead candidate identified – BL-017881, demonstrated pain reversal in the formalin paw model in mice.
For any partnering enquiries, please contact us here